Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

NCT00162006 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenic Purpura (ITP)

Interventions

DRUG: Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution

Sponsor

Baxalta now part of Shire